Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Simple item page
dc.contributor.authorMarth, Christian
dc.contributor.authorTarnawski, Rafal
dc.contributor.authorTyulyandina, Alexandra
dc.contributor.authorPignata, Sandro
dc.contributor.authorGilbert, Lucy
dc.contributor.authorKaen, Diego
dc.contributor.authorRubio, M. Jesus
dc.contributor.authorFrentzas, Sophia
dc.contributor.authorBeiner, Mario
dc.contributor.authorMagallanes-Maciel, Manuel
dc.contributor.authorFarrelly, Laura
dc.contributor.authorChoi, Chel Hun
dc.contributor.authorBerger, Regina
dc.contributor.authorLee, Christine
dc.contributor.authorVulsteke, Christof
dc.contributor.authorHasegawa, Kosei
dc.contributor.authorBraicu, Elena Ioanna
dc.contributor.authorWu, Xiaohua
dc.contributor.authorMcKenzie, Jodi
dc.contributor.authorLee, John J.
dc.contributor.authorMakker, Vicky
dc.contributor.authoraffiliation[Marth, Christian] Med Univ Innsbruck, AGO Austria & Dept Obstet & Gynaecol, Innsbruck, Austria
dc.contributor.authoraffiliation[Tarnawski, Rafal] Maria Sklodowska Curie Natl Res Inst, Oncol Gliwice Branch Abd PGOG, Gliwice, Poland
dc.contributor.authoraffiliation[Tyulyandina, Alexandra] CHRU Brest, Brest, France
dc.contributor.authoraffiliation[Tyulyandina, Alexandra] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
dc.contributor.authoraffiliation[Tyulyandina, Alexandra] Sechenov Univ, Sechenov First Moscow State Med Univ, Moscow, Russia
dc.contributor.authoraffiliation[Pignata, Sandro] Ist Nazl Tumori IRCCS Fdn G Pascale & MITO, Dept Urol & Gynecol, Naples, Italy
dc.contributor.authoraffiliation[Gilbert, Lucy] McGill Univ Hlth Ctr, Montreal, PQ, Canada
dc.contributor.authoraffiliation[Kaen, Diego] Ctr Oncol Riojano Integral & Natl Univ Rioja, La Rioja, Argentina
dc.contributor.authoraffiliation[Rubio, M. Jesus] H Reina Sofia Cordoba & GEICO Grp, Cordoba, Spain
dc.contributor.authoraffiliation[Frentzas, Sophia] Monash Hlth & Monash Univ, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Beiner, Mario] Meir Med Ctr & ISGO, Kefar Sava, Israel
dc.contributor.authoraffiliation[Magallanes-Maciel, Manuel] Ctr Oncol Internac, Mexico City, DF, Mexico
dc.contributor.authoraffiliation[Farrelly, Laura] Univ Coll London & NCRI, Canc Res UK & Univ Coll London Canc Trials Ctr, Inst Canc, London, England
dc.contributor.authoraffiliation[Choi, Chel Hun] Samsung Med Ctr, Seoul, South Korea
dc.contributor.authoraffiliation[Berger, Regina] Med Univ Innsbruck, AGO Austria & Univ Hosp Gynaecol & Obstet, Innsbruck, Austria
dc.contributor.authoraffiliation[Lee, Christine] Texas Oncol Woodlands, The Woodlands, TX USA
dc.contributor.authoraffiliation[Vulsteke, Christof] Univ Antwerp & BGOG, Integrated Canc Ctr Ghent, AZ Maria Middelares Ghent & Ctr Oncol Res, Dept Med Oncol, Antwerp, Belgium
dc.contributor.authoraffiliation[Hasegawa, Kosei] Saitama Med Univ, Int Med Ctr, Saitama, Japan
dc.contributor.authoraffiliation[Braicu, Elena Ioanna] Charite Univ Med Berlin, Berlin, Germany
dc.contributor.authoraffiliation[Braicu, Elena Ioanna] North Eastern German Soc Gynecol Oncol NOGGO, Berlin, Germany
dc.contributor.authoraffiliation[Wu, Xiaohua] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
dc.contributor.authoraffiliation[McKenzie, Jodi] Eisai Inc, Woodcliff Lake, NJ USA
dc.contributor.authoraffiliation[Lee, John J.] Merck Co Inc, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Makker, Vicky] Mem Sloan Kettering Canc Ctr, New York, NY USA
dc.contributor.authoraffiliation[Makker, Vicky] Weill Cornell, Med Ctr, New York, NY USA
dc.contributor.funderMerck Sharp & Dohme Corp, a subsidiary of Merck & Co Inc (Kenilworth, New Jersey, USA)
dc.contributor.funderNIH/NCI Cancer Center Support Grant
dc.contributor.funderEisai Inc (Woodcliff Lake, New Jersey, USA)
dc.date.accessioned2025-01-07T13:20:04Z
dc.date.available2025-01-07T13:20:04Z
dc.date.issued2021-11-18
dc.description.abstractBackground Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after
dc.identifier.doi10.1136/ijgc-2021-003017
dc.identifier.essn1525-1438
dc.identifier.issn1048-891X
dc.identifier.pmid34799418
dc.identifier.unpaywallURLhttps://ijgc.bmj.com/content/ijgc/32/1/93.full.pdf
dc.identifier.urihttps://hdl.handle.net/10668/25441
dc.identifier.wosID722241300001
dc.issue.number1
dc.journal.titleInternational journal of gynecological cancer
dc.journal.titleabbreviationInt. j. gynecol. cancer
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.number93-100
dc.publisherBmj publishing group
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePhase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeArticle

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía